Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
232 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (14)
  • (-) Currently Recruiting (2)
  • Closed (12)

Medical Condition

  • Show all (232)
  • Addiction (4)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (3)
  • Bone & Muscle (2)
  • Cancer (10)
    • Breast Cancer (2)
    • Gynecologic Cancer (1)
    • Leukemia (3)
    • Liver Cancer (1)
    • (-) Lymphoma (1)
    • Pancreatic Cancer (1)
  • COVID-19 (Coronavirus) (8)
  • Diabetes (7)
  • Ear, Nose and Throat (7)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Healthy Volunteers (46)
  • Heart Disease (21)
  • Infectious Disease (11)
  • Insomnia (1)
  • Liver Disease (15)
    • Cirrhosis of the Liver (1)
    • Liver Failure (1)
    • (-) MASH (formerly NASH) (1)
  • Lung Disease (2)
  • Neurological Disorders (31)
  • Nutrition (2)
  • Obesity (8)
  • Obstetrics & Gynecology (10)
  • Pediatrics (14)
  • Psychiatric Disorders (7)
  • Rehabilitation (2)
  • Stroke (2)
  • Transplant (12)
  • Vascular Conditions (1)
Displaying 1 - 2 of 2

Study to Test if BI 3802876 is Tolerated in People W/ Compensated Liver Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

Condition: Liver Disease / MASH (formerly NASH)
Investigator: Julia Wattacheril, MD, MPH
Status: Currently Recruiting
The purpose of this research study is to determine how well BI3802876 is tolerated in people living with cirrhosis due to a liver condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The study medication, BI3802876, is investigational, meaning it has not yet been approved by the United States Food and Drug…
Read More

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science